Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)

Main Article Content

RB Warren
A Blauvelt
J Bagel
KA Papp
P Yamauchi
A Armstrong
R Langley
V Vanvoorden
D De Cuyper
L Peterson
N Cross
K Reich


Plaque Psoriasis, Bimekizumab, IL-17A, IL-17F, Adalimumab, Biologic, Efficacy, Safety


Abstract not available.


1. Durham L. Curr Rheumatol Reports 2015;17:55

2. Fujishima S. Arch Dermatol Res 2010;302:499–505

3. Glatt S. Br J Clin Pharmacol 2017;83:991–1001

4. Papp KA. J Am Acad Dermatol 2018;79:277–86.e10

5. Reich K. AAD 2020, NCT03370133

6. Gordon K. AAD 2020, NCT03410992.

Similar Articles

You may also start an advanced similarity search for this article.